ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Organon & Co

Organon & Co (1OGN)

0,00
0,00
(0,00%)
Geschlossen 21 Juni 5:30PM

Organon & Co (1OGN) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
-
( - )
Gebot
-
Fragen
-
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
-
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
8.605.130 €
Ausgegebene Aktien
262.600.862
Dividendenrendite (LTM)
0,08 (0,60%)
Kurs-Gewinn-Verhältnis
14,26
Gewinn pro Aktie (EPS)
0,94
Erlöse (LTM)
6,16B
Nettogewinn (LTM)
246M

Über Organon & Co

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comp... Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Jersey City, United States
Gegründet
2026
Organon & Co is listed in the Healthcare sector of the Italienische Börse with ticker 1OGN. The last closing price for Organon & was -. Over the last year, Organon & shares have traded in a share price range of 0,00 € to 0,00 €.

Organon & currently has 262.600.862 shares in issue. Organon & has a price to earnings ratio (PE ratio) of 14.26.

1OGN Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

1OGN - Frequently Asked Questions (FAQ)

What is the current Organon & Co share price?
The current share price of Organon & Co is 0,00 €
How many Organon & Co shares are in issue?
Organon & Co has 262.600.862 shares in issue
What is the 1 year trading range for Organon & Co share price?
Organon & Co has traded in the range of 0,00 € to 0,00 € during the past year
What is the PE ratio of Organon & Co?
The price to earnings ratio of Organon & Co is 14,26
What is the cash to sales ratio of Organon & Co?
The cash to sales ratio of Organon & Co is 0,57
What is the registered address of Organon & Co?
The registered address for Organon & Co is 30 Hudson Street, Jersey City, New Jersey, 07302
What is the Organon & Co website address?
The website address for Organon & Co is www.organon.com
Which industry sector does Organon & Co operate in?
Organon & Co operates in the Pharmaceuticals sector

1OGN Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen